[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wet-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wet-macular-degeneration":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100650182","leap-strategy-for-neovascular-age-related-macular-degeneration-100650182",false,"NCT07744204","LEAP Strategy for Neovascular Age-Related Macular Degeneration","Laser-Enhanced Anti-VEGF Precise Penetration (LEAP) Strategy for Neovascular Age-Related Macular Degeneration: A Multicentre, Prospective, Stratified Block-Randomised Controlled Trial","LEAP","Inclusion Criteria:\n\n* Age ≥ 50 years, male or female\n* Diagnosed with neovascular age-related macular degeneration (nAMD) based on multimodal imaging (fundus photography, OCT, FFA, ICGA), including type 1, type 2, or type 3 MNV, or PCV\n* Clear ocular media and adequate pupillary dilation to permit OCT, fundus photography, angiography, and laser photocoagulation\n* Active MNV in the study eye at least partially located ≥ 300 μm from the foveal centre\n* Willing and able to provide written informed consent\n* Only one eye per subject enrolled; if both eyes eligible, the study eye is selected by the investigator\n\nExclusion Criteria:\n\n* Active MNV entirely located within 300 μm of the foveal centre\n* Significant hemorrhage obscuring the active MNV lesion on FFA\u002FICGA Unwilling or unable to provide informed consent, refusal of randomization, or inability to complete scheduled follow-up visits\n* Concurrent participation in other clinical trials\n* Contraindication or allergy to FFA\u002FICGA\n* Coexisting ocular conditions that may affect visual acuity during follow-up (e.g., cataract, diabetic retinopathy, retinal vascular occlusion, uveitis, neovascular glaucoma)\n* Severe ocular surface infection (e.g., conjunctivitis, severe blepharitis)\n* Uncontrolled hypertension (blood pressure \\> 180\u002F110 mmHg) despite antihypertensive therapy\n* Any condition in the study eye or systemically that, in the investigator's opinion, would pose significant risk to the participant\n* Poorly controlled blood glucose in diabetic patients\n* Transient ischemic attack, stroke, myocardial infarction, acute congestive heart failure, or other acute cardiovascular event requiring hospitalization within the past 4 months","ALL","50 Years","99 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background: Age-related macular degeneration (AMD) is a common eye disease that can cause blindness in older adults. The \"wet\" form of AMD, called neovascular AMD, happens when abnormal blood vessels grow under the retina and leak fluid. The current standard treatment requires repeated eye injections of anti-VEGF drugs, often every month or every few months. This frequent injection schedule is a heavy burden for patients and many cannot keep up with the treatment plan.\n\nPurpose: This study tests whether a single session of low-intensity laser applied to the diseased area, given just before the anti-VEGF injection, can help the drug reach the target more effectively. If this works, patients may need far fewer injections over time.\n\nIntervention: Participants will be randomly assigned to one of two groups. The experimental group will receive the laser treatment followed by an anti-VEGF injection within 6 hours. The control group will receive the anti-VEGF injection alone, according to the current standard regimen. Four different anti-VEGF drugs are allowed in this study: conbercept, aflibercept, ranibizumab, and faricimab.\n\nParticipants: The study plans to enroll at least 240 patients with active neovascular AMD across five hospitals in China. All participants must be at least 50 years old and meet specific eligibility criteria.\n\nFollow-up: All participants will be followed for 24 months with monthly clinic visits. The study will record the total number of injections received, changes in vision, fluid status on eye scans, and any side effects.\n\nPrimary Outcome: The main measure is the total number of anti-VEGF injections each participant needs over the 24-month period. The study will compare the experimental group and the control group to see whether the laser-enhanced approach reduces the injection frequency.",[28,29],"Neovascular Age-related Macular Degeneration(nAMD)","Wet Macular Degeneration","NOT_YET_RECRUITING","2026-08-18",{"date":33,"type":34},"2026-08-19","ACTUAL",{"date":36,"type":22},"2026-08-01",{"date":38,"type":22},"2029-07-31",{"name":40,"class":41},"Chinese PLA General Hospital","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100631122","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-003-100631122","NCT07496567","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-003)","A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2\u002F3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201\u002FMK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)","TORRONTES","The main inclusion criteria include but are not limited to the following:\n\n* Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)\n* The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment\n\nThe main exclusion criteria include but are not limited to the following\n\n* Has uncontrolled blood pressure at screening\n* History of any prior macular laser photocoagulation in the study eye\n* History of uveitis in either eye\n* History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study\n* Has uncontrolled glaucoma in the study eye\n* Active retinal disease other than the condition under investigation in the study eye\n* Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye",{"count":51,"type":22},960,[53,54],"PHASE2","PHASE3","Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).\n\nAvailable standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.\n\nThe goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.",[57,58,59,29],"Macular Degeneration","Age-Related Macular Degeneration","Choroidal Neovascularization","RECRUITING","2026-08-04",{"date":63,"type":34},"2026-08-06",{"date":65,"type":34},"2026-04-15",{"date":67,"type":22},"2028-07-31",{"name":69,"class":70},"EyeBiotech Ltd.","INDUSTRY",71,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":47,"acronym":77,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":55,"conditions":80,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100626791","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-002-100626791","NCT07440225","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-002)","MALBEC",{"count":51,"type":22},[53,54],[57,58,59,29],{"date":63,"type":34},{"date":83,"type":34},"2026-03-27",{"date":85,"type":22},"2028-06-30",{"name":69,"class":70},97]